Digital wearable therapeutics company Theranica has closed a $45 million series C funding round.
The funding will be used to expand Theranica's corporate reach in America. Theranica's flagship product is the wearable migraine treatment device Nerivio, according to an Aug. 29 Theranica news release.
New Rhein Healthcare Investors led the funding round.
"In spite of several decades of new medications, millions of individuals still suffer from frequent debilitating migraine headaches," Theranica CEO Alon Ironi said. "Over the last couple of years, we have verified the three fundamental conditions of a successful new prescribed therapy in the U.S.: healthcare providers have confidence in prescribing our Nerivio for treating migraine[s], patients get significant clinical benefit from using it, and [p]ayors realize the importance of providing their insured members with access to this therapy. With this triad demonstrated, we needed the appropriate funding to unleash the huge potential of Nerivio in the U.S.''